Screening for statin-related toxicity: The yield of transaminase and creatine kinase measurements in a primary care setting

Archives of Internal Medicine

Volumn 163, Issue 6, 2003, Pages 688-692

  Smith, C Christopher ^a   Bernstein, Lana I ^a   Davis, Roger B ^a   Rind, David M ^a   Shmerling, Robert H ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL CHEMISTRY; COMPUTER; CREATINE KINASE BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MEDICAL RECORD; MYALGIA; PATIENT INFORMATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; ANTICHOLESTEREMIC AGENTS; ASPARTATE AMINOTRANSFERASES; BOSTON; CREATINE KINASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MUSCULAR DISEASES; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; TRANSAMINASES;

EID: 0037463820     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.6.688     Document Type: Article

References (29)

1. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;334:1383-1389.
2. Cholesterol and Recurrent Events (CARE) Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
3. The LIPID Study Group. Prevention of cardiovascular events with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
4. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
6. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med. 1998;158:577-584.
7. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1996;156:2085-2092.
8. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol. 1994;74:667-673.
9. Mevacor. In: Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co; 1998:1694-1698.
10. Zocor. In: Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co; 1998:1776-1780.
11. Pravachol. In: Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co; 1998:808-811.
12. Lescol. In: Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co; 1998:1862-1865.
13. Lipitor. In: Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co; 1998:2186-2189.
14. Baycol. In: Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co; 1998:603-606.
15. Jokubaitis LA. Updated clinical safety experience with fluvastatin. Am J Cardiol. 1994;73:18D-24D.
16. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors. Arch Intern Med. 2000;160:2273-2280.
17. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498-511.
18. Choice of lipid-regulating drugs. Med Lett Drugs Ther. 2001;43:43-48.
19. Rosenson R. Lipid lowering with HMG-CoA reductase inhibitors (statins). In: Rose BD, ed. UpToDate [book on CD-ROM] Wellesley, Mass: UpToDate; 2000.
20. Santinga, J, Rosman HS, Rubenfire M, et al. Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia. Am J Med. 1994;96:509-515.
21. Stein E, Isaacsohn J, Stoltz R, et al. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia. Am J Cardiol. 1999;83:1433-1437.
22. Marz W, Wollschlager H, Klein G, Neiss A, Wehling M. Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE Trial). Am J Cardiol. 1999;84:7-13.
23. Boccuzzi SJ, Bocanegra TS, Walker JF, Shapiro DR, Keegan ME. Long-term safety and efficacy profile of simvastatin. Am J Cardiol. 1991;68:1127-1131.
24. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
25. Batalla A, Hevia S, Reguero JR, Cubero GI. Underutilization of lipid-lowering therapy in coronary artery disease. Arch Intern Med. 2000;160:2683-2684.
26. Cohen M, Byrne M, Levine B, Gutowski T, Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation. 1991;83:1294-1304.
27. Majumdar SR, Gurwitz JH, Soumorai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med. 1997;14:711-717.
28. McBride P, Schrott H, Plane M, Underbakke G, Brown RL. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med. 1998;158:1238-1244.
29. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S, for the HERS Research Group. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease: the Heart and Estrogen/Progestin Replacement Study (HERS). JAMA. 1997;277:1281-1286.